Alectinib was the next screened ALK-TKIs, wherein ALEX trial inferred its preferential first-line treatment, ascertained via response of 303 untreated ALK-positive advanced NSCLC sufferers, randomized to receive alectinib or crizotinib. This evidence concerns the gene ALK and non-small cell lung carcinoma.